178 related articles for article (PubMed ID: 19107520)
21. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
[TBL] [Abstract][Full Text] [Related]
22. Expression of metabolically targeted biomarkers in endometrial carcinoma.
Wahl H; Daudi S; Kshirsagar M; Griffith K; Tan L; Rhode J; Liu JR
Gynecol Oncol; 2010 Jan; 116(1):21-7. PubMed ID: 19878980
[TBL] [Abstract][Full Text] [Related]
23. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
[TBL] [Abstract][Full Text] [Related]
25. Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.
Quan P; Moinfar F; Kufferath I; Absenger M; Kueznik T; Denk H; Zatloukal K; Haybaeck J
Anticancer Res; 2014 Jun; 34(6):2883-97. PubMed ID: 24922651
[TBL] [Abstract][Full Text] [Related]
26. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy.
Faried LS; Faried A; Kanuma T; Aoki H; Sano T; Nakazato T; Tamura T; Kuwano H; Minegishi T
Mol Carcinog; 2008 Jun; 47(6):446-57. PubMed ID: 18058806
[TBL] [Abstract][Full Text] [Related]
27. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
[TBL] [Abstract][Full Text] [Related]
28. Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy.
Xiao L; Yang YB; Li XM; Xu CF; Li T; Wang XY
J Cancer Res Clin Oncol; 2010 Jul; 136(7):1089-99. PubMed ID: 20087603
[TBL] [Abstract][Full Text] [Related]
29. [Activation of mTOR signaling pathway in cancer stem cells of nasopharyngeal carcinoma and inhibitive effect of rapamycin against the cancer stem cells].
Zhang Y; Lin R; Zhang Z; Chen J; Yang C; Zhou L; Zhang Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jul; 29(13):1179-84. PubMed ID: 26540919
[TBL] [Abstract][Full Text] [Related]
30. Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma.
Shen Q; Stanton ML; Feng W; Rodriguez ME; Ramondetta L; Chen L; Brown RE; Duan X
Int J Clin Exp Pathol; 2010 Nov; 4(1):13-21. PubMed ID: 21228924
[TBL] [Abstract][Full Text] [Related]
31. Metformin Enhances Nomegestrol Acetate Suppressing Growth of Endometrial Cancer Cells and May Correlate to Downregulating mTOR Activity In Vitro and In Vivo.
Cao C; Zhou JY; Xie SW; Guo XJ; Li GT; Gong YJ; Yang WJ; Li Z; Zhong RH; Shao HH; Zhu Y
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284427
[TBL] [Abstract][Full Text] [Related]
32. Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients.
Clark C; Shah S; Herman-Ferdinandez L; Ekshyyan O; Abreo F; Rong X; McLarty J; Lurie A; Milligan EJ; Nathan CO
Laryngoscope; 2010 Jun; 120(6):1159-65. PubMed ID: 20513033
[TBL] [Abstract][Full Text] [Related]
33. Mammalian target of rapamycin is activated in association with myometrial proliferation during pregnancy.
Jaffer S; Shynlova O; Lye S
Endocrinology; 2009 Oct; 150(10):4672-80. PubMed ID: 19589861
[TBL] [Abstract][Full Text] [Related]
34. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
[TBL] [Abstract][Full Text] [Related]
35. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
36. eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy.
Huang CI; Wang CC; Tai TS; Hwang TZ; Yang CC; Hsu CM; Su YC
PLoS One; 2019; 14(11):e0225537. PubMed ID: 31756179
[TBL] [Abstract][Full Text] [Related]
37. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
[TBL] [Abstract][Full Text] [Related]
38. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
39. Inhibiting 4EBP1 in Glioblastoma.
Fan QW; Nicolaides TP; Weiss WA
Clin Cancer Res; 2018 Jan; 24(1):14-21. PubMed ID: 28696243
[TBL] [Abstract][Full Text] [Related]
40. Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene.
Martin D; Nguyen Q; Molinolo A; Gutkind JS
Oncogene; 2014 May; 33(18):2405-12. PubMed ID: 23708663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
